Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

The next wave: 10 promising investigational antihypertensive drugs to watch

By Brian Buntz | March 17, 2023

Measure of blood pressure with sphygmomanometer; panoramic banner

[Image courtesy of Adobe Stock]

Cardiovascular diseases remain a leading cause of morbidity and mortality worldwide. This review highlights ten promising antihypertensive drug candidates with the potential to address pulmonary arterial hypertension (PAH), resistant hypertension and uncontrolled hypertension.

Aprocitentan, developed by Janssen NYSE:JNJ) and Idorsia (SIX:IDIA), is an experimental oral drug designed to treat resistant hypertension. As a dual endothelin receptor antagonist (ERA), it effectively blocks the binding of ET-1 to both ET A and ET B receptors. The drug has a low likelihood of interacting with other medications and its mechanism of action is well-suited for treating resistant hypertension. In clinical trials, aprocitentan demonstrated better blood pressure reduction than placebo, with the effects lasting up to week 40, and was generally well-tolerated by patients. (Text continues beneath the following table:)

Drug Name Phase of Development Company Target Indication Notes
Aprocitentan Phase 3 Janssen/Idorsia Resistant hypertension Idorsia filed an NDA with the FDA for difficult-to-control hypertension in December 2022
Sotatercept Phase 3 Merck Pulmonary arterial hypertension (PAH) Advanced to Phase 3 with positive results
Ralinepag Phase 3 United Therapeutics Pulmonary arterial hypertension (PAH) Encouraging Phase 2 results; currently in Phase 3
XXB750 Phase 2 Novartis Resistant hypertension and heart failure with preserved ejection fraction Pursuing indications for Resistant Hypertension and Heart Failure with Preserved Ejection Fraction
Zilebesiran Phase 2 Alnylam Uncontrolled hypertension Novel mechanism of action
IONIS-AGT-LRx Phase 2 Ionis Pharmaceuticals Uncontrolled hypertension Novel antisense oligonucleotide inhibitor
Baxdrostat Phase 2 AstraZeneca/CinCor Resistant hypertension Potentially addresses a challenging form of hypertension with limited treatment options, but underwhelming performance in phase 2 HALO trial
L606 Phase 3 Pharmosa Biopharm Inc. Pulmonary arterial hypertension (PAH) Positive results from phase 2
Lorundrostat Phase 2 Mineralys Uncontrolled hypertension Positive results from phase 2

Merck & Co.’s (NYSE: MRK) sotatercept has received breakthrough therapy status from FDA and reported positive Phase 3 results for PAH pulmonary arterial hypertension (PAH), a life-threatening condition involving high blood pressure in the arteries of the lungs. Additionally, Arena Pharmaceuticals, recently acquired by Pfizer (NYSE:PFE), has demonstrated encouraging Phase 2 results for the antihypertensive ralinepag, which is now in Phase 3 for PAH. This drug candidate could potentially offer a new therapeutic strategy for PAH patients who do not respond well to existing treatments.

Drugs in Phase 2 trials include XXB750 from Novartis (NYSE:NVS), which holds potential for resistant hypertension, a condition that often requires complex and aggressive treatment strategies. This antihypertensive compound may offer a new treatment option for patients who fail to achieve blood pressure control with standard therapies. Also in Phase 2 is Alnylam’s (Nasdaq:ALNY) zilebesiran, which has a novel mechanism of action for hypertension, potentially leading to more effective and personalized treatment options.

In the same category is IONIS-AGT-LRx from Ionis (Nasdaq:IONS), which targets uncontrolled hypertension, a condition where blood pressure remains high despite treatment with medications. This investigational drug aims to improve blood pressure control for patients who have difficulty managing their hypertension. Baxdrostat, CinCor‘s lead asset, is also in Phase 2 for resistant hypertension. AstraZeneca (LON:AZN) acquired the company in February, further bolstering the drug’s prospects for successful development.

In early March, Mineralys Therapeutics announced positive data from its Target-HTN Phase 2 study, showing significant blood pressure reduction in hypertensive patients receiving once-daily lorundrostat. The study supports the hypothesis linking obesity, aldosterone and hypertension. The company believes lorundrostat has the potential for use earlier in the treatment paradigm for hypertension than current therapies.

The table above is based on factors such as clinical trial phases, obtained results, and potential impact on patient populations. We selected the following investigational drugs based on their potential impact in hypertension and PAH management from recent clinical studies. Criteria include the stage of development, target indications, which included PAH and uncontrolled and resistant hypertension. We also considered the novelty of the drug candidates’ mechanism of action as well as company reputation and experience.


Filed Under: Cardiovascular
Tagged With: Alnylam, Arena Pharmaceuticals, AstraZeneca, baxdrostat, CinCor, hypertension, Ionis, IONIS-AGT-LRx, L606, Merck & Co., Novartis, Pfizer, Pharmosa Biopharm Inc, pulmonary arterial hypertension (PAH), ralinepag, resistant hypertension, RMJ Holdings., sotatercept, XXB750, zilebesiran
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Sanofi ramps up distribution of Beyfortus ahead of RSV season
BMS
Label update broadens Camzyos reach in obstructive HCM, trims echo burden for stable patients
FDA logo
FDA drug approvals holding steady at 44 YTD in 2024
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE